Cardiovascular physiology

Blood Pressure Monitoring Market Revenue to Cross USD 2.9B by 2026: Global Market Insights, Inc.

Retrieved on: 
Wednesday, August 12, 2020
Physical quantities, Hypertension, Branches of biology, Cardiovascular system, Cardiovascular physiology, Pressure, Blood pressure measurement, Chronic condition, Blood pressure, Cardiovascular disease, Management of hypertension

The high burden of chronic diseases, especially cardiovascular diseases, will drive the blood pressure monitoring market revenue.

Key Points: 
  • The high burden of chronic diseases, especially cardiovascular diseases, will drive the blood pressure monitoring market revenue.
  • Hypertension/high blood pressure is a serious medical condition that substantially elevates the risk of heart, kidney brain, and other diseases.
  • The manual blood pressure monitoring market valued at over USD 656 million in 2019, led by growing adoption among healthcare professionals, owing to accuracy in blood pressure measurement.
  • Germany's blood pressure monitoring market accounted for over a 16% revenue share in 2019.

Latest Data from HouseCanary Reveals Cracks in the Housing Market are Reemerging

Retrieved on: 
Thursday, August 6, 2020
REIT, Residential Building & Real Estate, Technology, Construction & Property, Software, Cardiovascular physiology, Pulse, Financial services, Service industries

HouseCanary, Inc. (HouseCanary), a leading provider of residential real estate data and home valuations, today released its latest Market Pulse report, covering 22 listing-derived metrics and comparing data between the week ending July 31, 2020 and the week ending March 13, 2020.

Key Points: 
  • HouseCanary, Inc. (HouseCanary), a leading provider of residential real estate data and home valuations, today released its latest Market Pulse report, covering 22 listing-derived metrics and comparing data between the week ending July 31, 2020 and the week ending March 13, 2020.
  • The Market Pulse is an ongoing review of proprietary data and insights from HouseCanarys nationwide platform.
  • View the full release here: https://www.businesswire.com/news/home/20200806005348/en/
    HouseCanary Market Pulse Report (Graphic: Business Wire)
    Jeremy Sicklick, Co-founder and Chief Executive Officer of HouseCanary, commented: Some cracks in the housing market are beginning to surface now that new listing prices are dropping across more than 30 states even as supply constraints grow more pronounced.
  • Be sure to review the Market Pulse in full for extensive state-level data.

The Global Ambulatory Blood Pressure Monitoring Systems Market is expected to grow by $ 36.58 mn during 2020-2024 progressing at a CAGR of 11% during the forecast period

Retrieved on: 
Wednesday, August 5, 2020
Cardiovascular physiology, Pressure, Branches of biology, Medical specialties, Medicine, Ambulatory blood pressure, Monitoring, Blood pressure

The analyst has been monitoring the ambulatory blood pressure monitoring systems market and it is poised to grow by $ 36.58 mn during 2020-2024 progressing at a CAGR of 11% during the forecast period.

Key Points: 
  • The analyst has been monitoring the ambulatory blood pressure monitoring systems market and it is poised to grow by $ 36.58 mn during 2020-2024 progressing at a CAGR of 11% during the forecast period.
  • Our reports on ambulatory blood pressure monitoring systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The ambulatory blood pressure monitoring systems market analysis includes product segment and geographic landscape.
  • The ambulatory blood pressure monitoring systems market is segmented as below:

Europe Blood Collection Devices Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Method ; End User, and Country

Retrieved on: 
Tuesday, July 28, 2020
Medical specialties, Hematology, Branches of biology, Cardiovascular physiology, Veins, Blood, Transfusion medicine, Venipuncture

Factors such as risks associated with the blood collection devices damage the growth of the market.

Key Points: 
  • Factors such as risks associated with the blood collection devices damage the growth of the market.
  • Additionally, technological developments in blood collection techniques and products and increasing government initiatives for blood safetyare likely to fuel the growth of the blood collection devices market during the forecast period.
  • Blood collection devices help in safe withdrawal of blood from the donor to perform various diagnostic tests.Needles & syringes, lancets, and other devices are used for arterial and venous blood collection.
  • Based on product, the blood collection devices market is segmented into blood collection tubes, blood collection needles/holders, blood collection sets, and others.In 2019, the blood collection needles/holders segment accounted for the largest share of the blood collection devices market.

Venock Inc. Paves the Way for First Universal Large Bore Vascular Closure System Designed for Veins and Arteries

Retrieved on: 
Friday, July 24, 2020
Biotechnology, Surgery, Medical devices, Health, Cardiology, Cardiovascular system, Circulatory system, Angiology, Cardiovascular physiology, Medical specialties, Blood vessel, Vein, Artery, Vascular access, Interventional radiology, Angioplasty

All such therapies are facing growing demand and require large bore vascular access, with sites that can be as big as the diameter of the vessel itself.

Key Points: 
  • All such therapies are facing growing demand and require large bore vascular access, with sites that can be as big as the diameter of the vessel itself.
  • We invested a great deal of effort to expand our large bore venous closure technology to include closure of large bore arterial perforations.
  • Venock is developing the first universal large bore closure device for veins and arteries.
  • Its Vascular Closure Device is designed to close very large perforations that can be as big as the diameter of the vein or the artery.

Caption Health Receives FDA 510(k) Clearance for Innovation in Point-of-Care Ejection Fraction Evaluation

Retrieved on: 
Thursday, July 23, 2020
Cardiovascular physiology, Ejection fraction, Ejection, EF, Medical ultrasonography, Cardiac imaging

Caption Interpretation applies end-to-end deep learning to automatically select the best clips from ultrasound exams, perform quality assurance and produce an accurate EF measurement.

Key Points: 
  • Caption Interpretation applies end-to-end deep learning to automatically select the best clips from ultrasound exams, perform quality assurance and produce an accurate EF measurement.
  • The technology incorporates three ultrasound views into its fully automated ejection fraction calculation: apical 4-chamber (AP4), apical 2-chamber (AP2) and the readily-obtained parasternal long-axis (PLAX) viewan industry first.
  • Caption Health broke new ground in 2018 when it received the first FDA clearance for a fully automated EF assessment software.
  • Caption Interpretation works in tandem with Caption Guidance, cleared by the FDA earlier this year , as part of the Caption AI platform.

XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke

Retrieved on: 
Tuesday, July 14, 2020
Neurotrauma, Cardiovascular system, Circulatory system, Medical specialties, Cardiovascular physiology, Reperfusion injury, Stroke, Brain damage, Ischemia, Brain ischemia, Animal model of ischemic stroke

The publication titled, Post-Ischemic Administration of IL-1a Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke , points to a use for XBiotechs drug candidate antibody that blocks interleukin-1 alpha (IL-1) for use as a therapeutic to reduce brain damage and neurological deficit after stroke.

Key Points: 
  • The publication titled, Post-Ischemic Administration of IL-1a Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke , points to a use for XBiotechs drug candidate antibody that blocks interleukin-1 alpha (IL-1) for use as a therapeutic to reduce brain damage and neurological deficit after stroke.
  • Dr. Camicis research team tested an anti-IL-1 antibody provided by XBiotech to evaluate its ability to reduce brain injury in animals subjected to an experimental stroke and reperfusion injury.
  • Dr. Camicis research team focused on a particular difficult aspect of ischemic stroke, so called reperfusion injury.
  • When patients suffer from a stroke, or a blockage in an artery that provides crucial blood and oxygen to the brain, a portion of the brain typically suffers irreparable damage.

Intracranial Arterial Diseases: Global Pipeline Landscape Overview 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020
Health, Pharmaceutical, Angiology, Artery, Cardiovascular physiology

The "Intracranial Arterial Diseases - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intracranial Arterial Diseases - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the Intracranial Arterial Diseases pipeline landscape is provided, which includes the disease overview and Intracranial Arterial Diseases treatment guidelines.
  • The assessment part of the report embraces in-depth Intracranial Arterial Diseases commercial assessment and clinical assessment of the Intracranial Arterial Diseases pipeline products from the pre-clinical developmental phase to the marketed phase.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Intracranial Arterial Diseases.

Ancora Heart Receives IDE Approval for CorCinch-HF Pivotal Study of the AccuCinch® Ventricular Restoration System

Retrieved on: 
Tuesday, June 30, 2020
Surgery, Medical devices, FDA, Clinical trials, Cardiology, Biotechnology, Other Health, Health, General Health, Cardiovascular system, Branches of biology, Circulatory system, Cardiovascular physiology, Heart diseases, Medical devices, Prosthetics, Heart failure, RTT, Ejection fraction, Ventricle, Systole, Heart Failure, the AccuCinch Ventricular Restoration System, Ancora Heart

Ancora Heart, Inc. , a company developing a novel therapy to address heart failure, today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the CorCinch-HF pivotal study, which is designed to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).

Key Points: 
  • Ancora Heart, Inc. , a company developing a novel therapy to address heart failure, today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the CorCinch-HF pivotal study, which is designed to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
  • The AccuCinch System is the first completely percutaneous device designed to directly reshape the left ventricle of the heart, thereby addressing the fundamental issue in the progression of systolic heart failure.
  • Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to helping people with heart failure feel better and live longer.
  • Ancora Heart has developed the AccuCinch Ventricular Restoration System, an investigational device therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure.

HouseCanary’s Market Pulse Reveals U.S. Housing Market is Showing Meaningful Signs of Strength

Retrieved on: 
Thursday, June 25, 2020
Other Construction & Property, Residential Building & Real Estate, Technology, Construction & Property, Software, Cardiovascular physiology, Pulse, Academic disciplines

The Market Pulse is an ongoing review of proprietary data from the HouseCanary data platform spanning 44 states and the District of Columbia with sufficient property listing and transaction volume.

Key Points: 
  • The Market Pulse is an ongoing review of proprietary data from the HouseCanary data platform spanning 44 states and the District of Columbia with sufficient property listing and transaction volume.
  • This weeks data shows that the housing market has continued to bounce back from its lowest levels in mid-April, as contract volume is at or above pre-pandemic levels for the seventh consecutive week.
  • Increased confidence, pent-up demand and historically low interest rates will likely continue to drive contract volume in the weeks to come.
  • Additional findings from this weeks Market Pulse report include:
    Down 24.5% nationwide compared to the week ending March 13, when most COVID-19 measures were implemented
    Decline in new listing activity since the week ending March 13, broken down by home price: